Benoît Rousseau, MD, PhD

Assistant Attending
Benoît Camelli-Rousseau

Email

rousseab@mskcc.org

My research interests are in creating innovative immunomodulatory options for patients with immunologically “cold” tumors with a particular interest in antigens processing and maturation. Using in vitro and pre-clinical methods we are identifying ways of generating a “cold-to-hot” immune environment, with the goal of translating these results into a clinical trial.

Publications

Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, Azoulay D, Salloum C, Laurent A, de la Taille A, Salomon L, Cholley I, Haioun C, Dupuis J, Wolkenstein P, Matignon MB, Grimbert P, Tournigand C. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019 Feb 15;144(4):886-896.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch T, Rousseau B, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès Fridman C. Intra-tumor tertiary lymphoid structures are associated with a low risk of early tumor recurrence in patients with hepatocellular carcinoma. J Hepatol. 2019 Jan;70(1):58-65.

Bourdais R, Rousseau B, Pujals A, Boussion H, Joly C, Guillemin A, Baumgaertner I, Neuzillet C, Tournigand C. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Crit Rev Oncol Hematol. 2017 May;113:242-248.

J Fontugne, J Augustin, Anaïs Pujals, P Compagnon, B Rousseau, A Luciani, C Tournigand, D Cherqui, D Azoulay, JM Pawlotsky, J Calderaro. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017 Apr 11;8(15):24644-24651.

J Calderaro, B Rousseau, G Amaddeo, M Mercey, C Charpy, C Costentin, A Luciani, ES Zafrani, A Laurent, D Azoulay, F Lafdil, JM Pawlotsky, PD‐L1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology. 30 June 2016.

B. Rousseau, P. Loulergue, O. Mir et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the Vacance study. Ann Oncol. 2012 Feb;23(2):450-7. Epub 2011 May 16.

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Benoît Rousseau discloses the following relationships and financial interests:

  • Artios Pharma Limited
    Professional Services and Activities (Uncompensated)
  • Bpifrance
    Professional Services and Activities (Uncompensated)
  • Neophore
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures